California State Teachers Retirement System reduced its holdings in shares of Omeros Corporation (NASDAQ:OMER) by 7.3% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 73,794 shares of the biopharmaceutical company’s stock after selling 5,842 shares during the period. California State Teachers Retirement System owned approximately 0.16% of Omeros Corporation worth $1,469,000 as of its most recent filing with the SEC.
A number of other institutional investors have also modified their holdings of OMER. EAM Investors LLC purchased a new position in Omeros Corporation during the 2nd quarter worth $3,083,000. Quantitative Investment Management LLC purchased a new position in Omeros Corporation during the 2nd quarter worth $2,979,000. Stifel Financial Corp grew its position in Omeros Corporation by 54.1% during the 2nd quarter. Stifel Financial Corp now owns 356,160 shares of the biopharmaceutical company’s stock worth $7,091,000 after purchasing an additional 125,110 shares during the last quarter. Vanguard Group Inc. grew its position in Omeros Corporation by 5.4% during the 2nd quarter. Vanguard Group Inc. now owns 1,825,671 shares of the biopharmaceutical company’s stock worth $36,341,000 after purchasing an additional 94,280 shares during the last quarter. Finally, State Street Corp grew its position in Omeros Corporation by 7.3% during the 2nd quarter. State Street Corp now owns 987,057 shares of the biopharmaceutical company’s stock worth $19,652,000 after purchasing an additional 66,827 shares during the last quarter. 45.38% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://sportsperspectives.com/2017/11/20/omeros-corporation-omer-shares-sold-by-california-state-teachers-retirement-system.html.
Shares of Omeros Corporation (NASDAQ OMER) opened at $19.81 on Monday. The company has a current ratio of 4.77, a quick ratio of 4.74 and a debt-to-equity ratio of 8.99. Omeros Corporation has a fifty-two week low of $8.71 and a fifty-two week high of $27.09.
Omeros Corporation (NASDAQ:OMER) last issued its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.18. The firm had revenue of $21.66 million during the quarter, compared to analysts’ expectations of $17.82 million. The firm’s revenue was up 91.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.34) EPS. analysts forecast that Omeros Corporation will post -1.07 EPS for the current year.
OMER has been the topic of several research reports. Maxim Group set a $24.00 price objective on shares of Omeros Corporation and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. Wedbush reissued an “outperform” rating and set a $47.00 price objective on shares of Omeros Corporation in a research report on Friday, August 18th. Cantor Fitzgerald reissued a “hold” rating and set a $19.00 price objective (up from $15.00) on shares of Omeros Corporation in a research report on Thursday, August 24th. Zacks Investment Research raised shares of Omeros Corporation from a “hold” rating to a “strong-buy” rating and set a $22.00 price objective on the stock in a research report on Thursday, October 19th. Finally, Cowen and Company downgraded shares of Omeros Corporation from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 2nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $34.14.
Omeros Corporation Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.